Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Department of Veterans Affairs Eli Lilly and Company |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00018174 |
This project is a treatment-matching study to test whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation goals for the smoker who lacks a history of depression. The study target is to randomize 120 smokers with a prior history of depression and 120 smokers who lack such a history to a double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo cognitive behavioral treatment to quit smoking.
Condition | Intervention | Phase |
---|---|---|
Depression Smoking |
Drug: Fluoxetine Behavioral: Behavioral group smoking cessation treatment Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study |
Official Title: | Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers |
Enrollment: | 247 |
Study Start Date: | February 1998 |
Study Completion Date: | January 2005 |
Primary Completion Date: | January 2003 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental | Drug: Fluoxetine Behavioral: Behavioral group smoking cessation treatment |
2: Placebo Comparator | Behavioral: Behavioral group smoking cessation treatment Drug: Placebo |
The aim of this research is to examine whether adding antidepressant pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit, while not undermining cessation for the smoker who lacks a history of depression, by randomizing smokers both with and without such a history to double-blind treatment with either 60 mg fluoxetine or placebo. The primary Depressive Episode Hypothesis states that the stress of quitting smoking and the biological challenge of nicotine withdrawal trigger a depressive episode in vulnerable individuals. To the extent that episode onset can be prevented by prophylactic administration of antidepressant pharmacotherapy, smokers with a history of depression will show significantly higher abstinence rates when treated with fluoxetine than placebo, whereas no drug effect will be evident for history negative smokers who lack the depressive diathesis. An alternative generalized withdrawal hypothesis construes post-cessation dysphoria as one general manifestation of a nicotine withdrawal syndrome that occurs independently of depressive vulnerability, and predicts that fluoxetine, as compared to placebo, will uniformly improve cessation outcomes, regardless of whether smokers possess the diathesis for depression. Over period of four years, the study hopes to randomize 120 smokers with a history of depression and 120 smokers who lack such a history to double-blind treatment with either 60 mg fluoxetine or placebo, while they undergo group cognitive behavioral treatment to quit smoking. To allow plasma drug levels to stabilize before quitting smoking, drug or placebo treatment begins 3 weeks before quitting smoking and continues for an additional 8 weeks following the quit date. Participants will be followed up monthly for 4 months after the end of treatment in order to assess the main study outcome; abstinence from smoking 6 months after the quit date.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Subjects may not enter the trial if they:
Subjects with dysthymic disorder or anxiety disorders will be studied if their current symptoms are not sequelae of an episode of major depression. Excluding such cases would purify the sample by removing mild degrees of dysphoria, but would greatly restrict our ability to generalize any treatment implications to the current population that smokers.
United States, Illinois | |
Edward Hines, Jr. VA Hospital | |
Hines, Illinois, United States, 60141-3030 |
Principal Investigator: | Bonnie Spring, PhD | Edward Hines Jr. VA Hospital |
Responsible Party: | Department of Veterans Affairs ( Spring, Bonnie - Principal Investigator ) |
Study ID Numbers: | ADRD-011-97S |
Study First Received: | July 3, 2001 |
Last Updated: | February 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00018174 History of Changes |
Health Authority: | United States: Federal Government |
Depression Fluoxetine Nicotine dependence |
Nicotine polacrilex Neurotransmitter Agents Depression Psychotropic Drugs Depressive Disorder Serotonin Uptake Inhibitors Serotonin Behavioral Symptoms |
Fluoxetine Smoking Mental Disorders Nicotine Mood Disorders Antidepressive Agents, Second-Generation Antidepressive Agents |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Depression Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Depressive Disorder Serotonin Uptake Inhibitors Pharmacologic Actions Behavioral Symptoms |
Fluoxetine Smoking Habits Serotonin Agents Mental Disorders Therapeutic Uses Mood Disorders Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |